1. Presentation titleDate Growth disorders & Early referral Date: 13 th Oct 2015 Venue: Kermanshahi hospital hall Name: Elaheh Goodarzi Biopharm, Novo Nordisk Pars

2. Presentation titleDate 2 Agenda 1 3 2 Welcome and Novo Nordisk Introduction 4 Growth Disorders

3. Presentation titleDate Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 37,200 employees in 76 countries, and markets its products in more than180 countries. We are a global healthcare company….

4. Presentation titleDate Employees by geographical area … with more than 37,200 employees around the world

5. Presentation titleDate Novo Nordisk at a glance A world leader since 1923 in diabetes care in insulin in injection devices Also leading positions in: Haemostasis Management Growth Hormone Therapy Hormone Replacement Therapy (HRT)

6. Presentation titleDate 6 Our logo - The Apis Bull An Egyptian statuette dating from ca. 600 BC One of the deified animals of ancient Egypt. Reincarnation of Ptah, the god of science and art Also bears other symbols for life and health

7. Presentation titleDate Our business philosophy

8. Our values The Essentials are ten statements describing what the Novo Nordisk Way looks like in practice. They are meant as a help to our managers and employees for evaluating to what extent our organisation acts in accordance with the Novo Nordisk Way. 1.We create value by having a patient-centred business approach. 2.We set ambitious goals and strive for excellence. 3.We are accountable for our financial, environmental and social performance. 4.We provide innovation to the benefit of our stakeholders. 5.We build and maintain good relations with our key stakeholders. 6.We treat everyone with respect. 7.We focus on personal performance and development. 8.We have a healthy and engaging working environment. 9.We optimise the way we work and strive for simplicity. 10.We never compromise on quality and business ethics. Presentation titleDate

9. Presentation titleDate Novo Nordisk Pars Our affiliate was registered in 2004 & Started to work in 2005 actively with 4 employees

10. Presentation titleDate Novo Nordisk Pars at a glance Established in 2005 Part of business area near east i.e. BANE 100% owned by Novo Nordisk A/S Current number of employees: 78 employees Leader in diabetes care Also leading positions in: Haemostasis management Growth hormone therapy Hormone replacement therapy NN Iran Tehran

11. Presentation titleDate Biopharm therapy fields Haemostasis management Growth Hormone Therapy Hormone Replacement Therapy (HRT)

12. Presentation titleDate Haemostasis management Recombinant factor VIIa Used for treating bleeding episodes in: haemophilia patients with inhibitors to factor VIII & factor IX patients with acquired haemophilia patients with factor VII deficiency Glanzmann’s thrombasthenia

13. Presentation titleDate Growth Hormone Therapy Local manufacturing of human growth hormone Sole provider of hGH Around 60,000 patients 70% insurance coverage

14. Presentation titleDate Hormone Replacement Therapy (HRT) Novo Nordisk offers a range of HRT products for efficacious ultra-low- dose treatment of symptoms during women’s menopause

15. Presentation titleDate Local production 80% of all Novo Nordisk medicines are being sold in Iran are produced locally with Iranian partners

16. Presentation titleDate Measure height, measure health

17. Presentation titleDate For more information visit www.novonordisk.com